Molecular Templates (MTEM) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MTEM vs. AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, BMRN, INCY, and NBIXShould you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry. Molecular Templates vs. Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Amgen (NASDAQ:AMGN) and Molecular Templates (NASDAQ:MTEM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation. Does the media prefer AMGN or MTEM? In the previous week, Amgen had 58 more articles in the media than Molecular Templates. MarketBeat recorded 58 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 1.59 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the media. Company Overall Sentiment Amgen Very Positive Molecular Templates Neutral Do analysts prefer AMGN or MTEM? Amgen presently has a consensus price target of $314.04, indicating a potential upside of 2.71%. Given Amgen's stronger consensus rating and higher possible upside, research analysts plainly believe Amgen is more favorable than Molecular Templates.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.48Molecular Templates 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is AMGN or MTEM more profitable? Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Molecular Templates -61.35%-260.50%-46.90% Which has more volatility & risk, AMGN or MTEM? Amgen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Do institutionals & insiders have more ownership in AMGN or MTEM? 76.5% of Amgen shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 0.7% of Amgen shares are held by insiders. Comparatively, 13.9% of Molecular Templates shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, AMGN or MTEM? Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.91$4.09B$7.5540.50Molecular Templates$23.48M0.00-$8.12M-$2.70N/A Does the MarketBeat Community favor AMGN or MTEM? Amgen received 1209 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.87% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155171.87% Underperform Votes60728.13% Molecular TemplatesOutperform Votes34267.32% Underperform Votes16632.68% SummaryAmgen beats Molecular Templates on 15 of the 18 factors compared between the two stocks. Remove Ads Get Molecular Templates News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEM vs. The Competition Export to ExcelMetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3,000.00$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio0.007.2023.1419.03Price / SalesN/A226.01385.7893.17Price / CashN/A65.6738.1634.64Price / BookN/A6.476.934.33Net Income-$8.12M$141.90M$3.20B$247.06M Molecular Templates Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEMMolecular Templates0.7534 of 5 starsN/AN/AN/A$3,000.00$23.48M0.00260Gap UpAMGNAmgen4.4722 of 5 stars$317.17+1.1%$314.04-1.0%+6.8%$170.39B$33.42B42.0128,000Positive NewsGILDGilead Sciences4.6093 of 5 stars$112.26+0.7%$104.52-6.9%+52.3%$139.80B$28.75B303.4118,000Analyst ForecastPositive NewsVRTXVertex Pharmaceuticals3.8887 of 5 stars$513.76+1.8%$506.70-1.4%+20.4%$131.93B$11.02B-233.536,100Positive NewsREGNRegeneron Pharmaceuticals4.8436 of 5 stars$678.42+1.7%$973.13+43.4%-34.2%$74.17B$14.20B17.7211,900Short Interest ↑Positive NewsALNYAlnylam Pharmaceuticals4.2649 of 5 stars$253.11+4.7%$304.26+20.2%+75.5%$32.77B$2.25B-116.642,230BIIBBiogen4.9116 of 5 stars$143.54+2.9%$213.33+48.6%-35.1%$21.01B$9.68B12.838,720Positive NewsUTHRUnited Therapeutics4.9404 of 5 stars$322.94+5.1%$388.25+20.2%+26.6%$14.50B$2.88B14.18980Insider TradeShort Interest ↓Positive NewsBMRNBioMarin Pharmaceutical4.9038 of 5 stars$71.55+3.0%$94.00+31.4%-17.8%$13.65B$2.85B32.523,401Options VolumeINCYIncyte4.7096 of 5 stars$62.01-8.6%$75.25+21.4%+6.2%$12.00B$4.24B229.682,617Positive NewsHigh Trading VolumeNBIXNeurocrine Biosciences4.9292 of 5 stars$111.50+0.7%$165.24+48.2%-17.3%$11.12B$2.36B33.891,200Analyst ForecastNews CoveragePositive News Remove Ads Related Companies and Tools Related Companies AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors NBIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEM) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
